Financials in USD. Standardized financial statements.
A compact view of how IGM Biosciences, Inc. turns revenue into operating income and net income.
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|
| Revenue? | $2.68M | $2.13M | $1.07M | $0 | $0 | $0 | $0 | $0 |
| Revenue Growth? | +25.8% | +99.3% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Cost of Revenue? | $9.11M | $8.28M | $10.60M | $7.72M | $3.58M | $2.33M | $278,000 | $161,000 |
| Gross Profit? | -$6.43M | -$6.15M | -$9.53M | -$7.72M | -$3.58M | -$2.33M | -$278,000 | -$161,000 |
| Gross Margin? | -240.1% | -288.6% | -891.8% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Operating Expenses? | $211.26M | $265.59M | $229.03M | $165.32M | $83.28M | $44.50M | $22.79M | $11.15M |
| Operating Income? | -$208.58M | -$263.46M | -$227.96M | -$165.32M | -$83.28M | -$44.50M | -$22.79M | -$11.15M |
| EBITDA? | -$199.47M | -$255.18M | -$221.88M | -$157.44M | -$77.78M | -$40.80M | -$22.51M | -$10.99M |
| Income Before Tax | -$195.79M | -$245.74M | -$221.10M | -$165.16M | -$81.36M | -$43.13M | -$22.71M | -$11.05M |
| Income Tax Expense | $0 | $678,000 | $0 | $0 | $0 | $0 | $80,000 | $0 |
| Net Income? | -$195.79M | -$246.42M | -$214.25M | -$160.68M | -$80.33M | -$42.54M | -$22.71M | -$11.05M |
| EPS? | $-3.24 | $-4.71 | $-5.16 | $-4.80 | $-2.61 | $-4.73 | $-51.84 | $-25.24 |
| Diluted EPS? | $-3.24 | $-4.71 | $-5.16 | $-4.80 | $-2.61 | $-4.73 | $-51.84 | $-25.24 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality